Search

Displaying results 2351 - 2360 of 6951 in total
  1. Drug

    Camphor

    go.drugbank.com/drugs/DB01744
    ApprovedInvestigationalWithdrawn

    It appears in the list of drug products withdrawn or removed from the market for safety or effectiveness. … When ingested, camphor has a rapid onset of toxic effects, and camphorated oil is the product most often responsible for its toxicity.

    Mixtures: Thunas Salve for Rheumatic Pains, Orajel for Cold Sores Maximum Strength
  2. Drug

    Nitrofural

    go.drugbank.com/drugs/DB00336
    ApprovedVet approvedWithdrawn

    Except for topical drug products formulated for dermatologic application, the FDA withdrew its approval for the use of drug products containing nitrofurazone.[L43942] … It is used for superficial wounds, burns, ulcers, and skin infections. Nitrofural has also been administered orally in the treatment of trypanosomiasis.

  3. Drug

    Vismodegib

    go.drugbank.com/drugs/DB08828
    ApprovedInvestigational

    Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. … [A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma.

    Categories: Smoothened Receptor Antagonists
  4. Drug

    Ripretinib

    go.drugbank.com/drugs/DB14840
    ApprovedInvestigational

    Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]

    Categories: Stem Cell Factor (KIT) Receptor Inhibitors, Platelet-derived Growth Factor alpha Receptor Inhibitors
  5. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    [A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]

    Categories: Antihypertensive Agents Indicated for Hypertension
  6. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

  7. Drug

    Eprosartan

    go.drugbank.com/drugs/DB00876
    ApprovedInvestigational

    Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.

    Categories: Antihypertensive Agents Indicated for Hypertension, Angiotensin 2 Receptor Blocker
  8. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    The inhibited reaction is necessary in these organisms for the synthesis of folic acid. … Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally.

  9. Drug

    Fexinidazole

    go.drugbank.com/drugs/DB12265
    Approved

    all-oral treatment for first and second stage HAT caused by _T. brucei gambiense_. … [A237550] Historical treatment options for meningoencephalitic HAT include [melarsoprol], [eflornithine], and [nifurtimox]/[eflornithine] combination therapy (NECT), though [melarsoprol] is highly toxic

  10. Drug

    Baloxavir marboxil

    go.drugbank.com/drugs/DB13997
    ApprovedInvestigational

    Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation. It is a prodrug of baloxavir with an impro...

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use